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The cell of origin for basal cell carcinoma (BCC) remains controversial. In this issue ofCancer Cell, Wang et al.
provide strong evidence that BCC arise from hair follicle stem cells.Over twenty years ago, we localized
a population of presumptive stem cells
to the hair follicle bulge (Cotsarelis et al.,
1990). Bothmouse and human bulge cells
possess a quiescent phenotype that
markedly contrasts with the much higher
proliferative rate of the cells within the
remainder of the cutaneous epithelium
(Lyle et al., 1998). We proposed that bulge
cells were the site of origin for skin
cancers, primarily because their long-
lived nature would allow for accumulation
of multiple genetic hits and subsequent
tumor formation. At that time, we asked,
‘‘What are the relative contributions of
the follicle and IFE in giving rise to various
human skin carcinomas?’’ With respect to
cutaneous basal cell carcinoma, the most
common type of cancer, this question
awaited the development of molecular
tools for targeting bulge cells as well
as the development of mouse cancer
models.
Genetic lineage analysis of bulge cells
became possible with the discovery that
the Keratin 15 (K15) promoter preferen-
tially targets stem and progenitor cells in
the bulge and adjacent secondary germ
(Morris et al., 2004). The inducible K15-
CrePR1;R26Rmousewasused to demon-
strate that bulge cells generated all epithe-
lial lineages during hair follicle cycling
when the lower follicle regenerates and
that these cells contributed keratinocytes
to healing wounds (Ito et al., 2005; Morris
et al., 2004). The K15 promoter could
then be used to target bulge cells inmouse
models of skin cancer to determine if hair
follicle stemcells contributed tocutaneous
carcinogenesis.
Two recent studies took this approach
and came to diametrically opposite
conclusions. Blanpain and coworkers
published that basal cell carcinomas in
a transgenic overexpression model didnot arise from hair follicle bulge cells
(Youssef et al., 2010). In contrast, Epstein
and colleagues report that irradiated
Ptch1+/ mice develop BCCs almost
exclusively from hair follicle bulge cells
(Wang et al., 2011). Understanding this
discrepancy is critical for the field and
has implications on developing treat-
ments for human BCCs.
BCCs in humans occur spontaneously
or as part of hereditary syndromes such
as basal cell nevus syndrome (BCNS).
BCNS patients generally carry one
mutated PTCH1 gene, which encodes
a receptor for hedgehog proteins, and
develop BCCs through loss of heterozy-
gosity of the remaining PTCH1 allele.
The large majority of spontaneous basal
cell carcinomas also possess loss-of-
function mutations in the PTCH1 gene
that lead to activation of the hedgehog
pathway. Basal cell carcinomas without
PTCH1mutations may possess activating
mutations in genes encoding other
components in the hedgehog pathway
such as the signal transducer Smo
(SMO). Thus, mutations leading to activa-
tion of the hedgehog pathway are a hall-
mark of human basal cell carcinomas.
Since PTCH1 is a hedgehog target gene,
basal cell carcinomas overexpress
PTCH1 mRNA and this can be used as
a marker for basal cell carcinoma.
The hedgehog pathway is critical for
development of hair follicles. Interest-
ingly, in the normal adult epidermis, little
to no expression of Ptch or its ligand
Shh is evident. These genes are ex-
pressed primarily in the hair follicle and
only at specific times during hair follicle
cycling in the adult. This raises the possi-
bility that loss of Ptch in the interfollicular
epidermis (IFE) may not immediately
impact epidermal keratinocyte behavior.
Consistent with this, transgenic miceCancer Cellthat overexpress Shh in skin develop
tumor-like changes primarily in their hair
follicle epithelium rather than in their IFE
(Oro et al., 1997).
Human BCCs generally possess two
mutated alleles, often with UV signatures,
of PTCH1. Loss of Ptch function results in
overexpression of hedgehog target genes
since Ptch normally represses these.
Epstein and colleagues developed a
Ptch1+/ mouse that forms BCCs
following UV or ionizing radiation. This
mouse phenocopies the BCNS patient in
that both develop medulloblastomas and
rhabdomyoscarcomas as well as BCCs.
Thus, this mouse model seems ideal for
studying the development of BCC and
for answering the question of whether
BCCs arise from hair follicle bulge cells
or from other epithelial cells. Wang et al.
crossed this mouse with the K15-
CrePR;R26R-YFP mouse, induced la-
beling of the bulge cells, irradiated the
mice, then evaluated the resulting tumors
for expression of YFP that would indicate
a bulge cell origin (Wang et al., 2011).
Taking into account the efficiency of the
inducible system, they showed that the
great majority of BCCs arose from K15-
positive bulge cells.
The cell of origin of human BCC has
been debated for decades; however, der-
matopathologists generally hold the view
that ‘‘superficial (multicentric)’’ BCCs
arise from IFE while some portion of
nodular BCCs arise from the follicle.
Previous studies on humanBCCs showed
that most of these tumors express kera-
tins associated with follicular keratino-
cytes. Interestingly, when immunostained
for K15 protein, the bulge cell marker,
approximately one third of nodular BCCs
stained positive, while none of the super-
ficial BCCs stained, thus providing
evidence that a substantial portion of19, January 18, 2011 ª2011 Elsevier Inc. 5
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Previewshuman nodular BCCs arise from the hair
follicle bulge (Jih et al., 1999).
Other types of mouse models for basal
cell carcinoma depend on overexpression
of genes in the hedgehog pathway, such
as Gli and Smo; for example, targeting
of Gli expression to the follicle and IFE
results in the formation of basal cell
tumors that clinically resemble human
basal cell carcinomas in that they have
a translucent appearance and the pres-
ence of small vessels known as telangiec-
tasias (Grachtchouk et al., 2000; Nilsson
et al., 2000). These tumors are dependent
on continuous Gli expression and regress
if the transgene is turned off. Results of
early clinical trials suggest that human
BCCs are similarly ‘‘addicted’’ to hedge-
hog signaling and may be amenable to
targeted therapy.
Dlugosz and colleagues previously pub-
lished that constitutive overexpression of
activated Smo in the epidermis resulted
in basaloid hamartomas (Grachtchouk
et al., 2003). These investigators were
careful to distinguish between basaloid
hamartomas and BCC because basaloid
hamartomas, both in humans and in
mice, have limited growth potential and
rarely develop into BCC. In a more recent
study, Blanpain and colleagues also over-
expressedactivatedSmo in the epidermis,
but with an inducible system, and6 Cancer Cell 19, January 18, 2011 ª2011 Eldescribed the formation of ‘‘basal cell
carcinomas.’’ (Youssef et al., 2010) One
problem with both the Blanpain and the
Wang paper rests on whether the tumors
that developed are truly BCCs or whether
they are basaloid hamartomas. Input
from a dermatopathologist is essential for
making the distinction, but marker studies
would be ideal. Nonetheless, these find-
ings do suggest that non-bulge cells have
a lower threshold thanbulgecells for tumor
development in response to oncogenic
Smo.
Wang et al. suggest that loss of p53
triggers Smo expression in epidermis of
Ptch1+/mice. Since Smo is an obligatory
activator of Hh signaling, the resultant
epidermal BCCs in irradiated p53-defi-
cient Ptch1+/ mice suggests that loss of
p53 may be a primary event in BCC
formation, operating through the novel
mechanism of Smo upregulation. This
important concept deserves testing in
both human epidermis with known p53
mutations and inmousemodels. The find-
ings could impact on future targeting of
incipient BCC with chemotherapeutic
agents.REFERENCES
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In this issue of Cancer Cell, Sonoshita et al. report that Aes/Grg5 prevents metastasis of colorectal cancer
cells by sequestering and inactivating Notch transcriptional effectors in distinct nuclear foci. Loss of Aes/
Grg5 in invasive cancer cells where Notch is activated by stroma-expressed ligands promotes invasion,
transendothelial migration, intravasation, and metastasis.Metastatic disease is the major cause of
cancer-associated death. During the
metastatic process, cancer cells need to
overcome a number of hurdles, includinginvasion into neighboring tissue, intrava-
sation into blood or lymphatic vessels,
survival in the circulation, extravasation
from vessels at distant organs, and colo-nization and outgrowth at the distant
sites. Each of these events involves
a number of signaling pathways. In this
issue of Cancer Cell, Sonoshita and
